EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Durable response to sotorasib-based combination therapy in advanced lung adenocarcinoma harboring KRAS G12C and STK11 mutations: a case report

Jiaqi Wang, Yaxin Yan, Quanbing Su, Yitao Jia

Frontiers in Oncology · 12.03.2026 · 16

DOI: 10.3389/fonc.2026.1776402 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 12.03.2026. Verfasst von Jiaqi Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Hebei General Hospital, Shijiazhuang, Hebei, China. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung adenocarcinoma is a prevalent and aggressive subtype of non-small cell lung cancer (NSCLC). Mutations in the Kirsten rat sarcoma viral oncogene homologue (KRAS) represent key oncogenic drivers and are associated with poor prognosis. Sotorasib is a KRAS G12C inhibitor. It suppresses tumor growth by specifically and irreversibly locking the mutant KRAS protein. Currently, sotorasib is only approved for later-line treatment of KRAS G12C-mutated NSCLC. Here, we present a case of advanced NSCLC harboring a KRAS G12C and STK11 mutations. The patient received an exploratory first-line therapy with sotorasib combined with immunotherapy and chemotherapy, achieving significant and durable clinical benefit lasting 23 months, with manageable adverse events. This case highlights the potential of sotorasib in combination regimens as a first-line treatment strategy for KRAS G12C-mutated NSCLC and underscores the importance of individualized treatment planning. However, the use of sotorasib in the first-line setting remains an exploratory off-label approach and requires further clinical evidence to validate this treatment strategy.

Schlagwörter

Stichwörter der Autor:innen

KRAS G12CSTK11heterogeneous immune phenotypelung adenocarcinomasotorasib

Autor:innen und Institutionen

  • Department of Oncology, Hebei General Hospital, Shijiazhuang, Hebei, China.

Zitieren

APA

Wang, J., Yan, Y., Su, Q., & Jia, Y. (2026). Durable response to sotorasib-based combination therapy in advanced lung adenocarcinoma harboring KRAS G12C and STK11 mutations: a case report. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1776402

Vancouver

Wang J, Yan Y, Su Q, Jia Y. Durable response to sotorasib-based combination therapy in advanced lung adenocarcinoma harboring KRAS G12C and STK11 mutations: a case report. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1776402

BibTeX
@article{Wang2026,
  author = {Wang, Jiaqi and Yan, Yaxin and Su, Quanbing and Jia, Yitao},
  title = {Durable response to sotorasib-based combination therapy in advanced lung adenocarcinoma harboring KRAS G12C and STK11 mutations: a case report},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1776402}
}
Kostenlos starten →